The aim of the present work was to develop pectin raft-forming tablets for controlled-release delivery of pantoprazole sodium sesquihydrate (PSS). A Box-Behnken design was used to optimize 15 formulations with three independent and three dependent variables. The physical tests of all compressed formulations were within pharmacopoeial limits. The rafts were characterized by their strength, thickness, resilience, reflux resistance, acid-neutralizing capacity, floating lag time, and total floating time. The raft strength, thickness, resilience, and reflux resistance through a 10-mm orifice of optimized formulation PR9 were 7.43 6 0.019 g, 5.8 6 0.245 cm, greater than 480 min, and 2490 6 0.004 g, respectively. The buffering and neutralizing capacity was 11.2 6 1.01 meq and 6.5 6 0.56 meq, respectively. Dissolution studies were performed by using simulated gastric fluid at pH 1.2, and the cumulative percentage release of PR9 was found to be 97%. First-order release kinetics were followed, and non-Fickian diffusion was observed as the value of n was greater than 0.45 in the Korsmeyer-Peppas model. The Fourier transform infrared spectra of the PSS, polymers, and optimized raft formulation PR9 showed peaks at 3223.09 cm 21 , 1688.17 cm 21 , 1586.67 cm 21 , 1302.64 cm 21 , and 1027.74 cm 21 that are due to AOH stretching, ester carbonyl group (C@O) stretching, the existence of water and carboxylic groups in the raft, CAN stretching, and AOH bending vibrations and showed no interaction between them. The developed raft was suitable for sustained-release delivery of PSS.